Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024

SAN FRANCISCO and SUZHOU, China, Sept. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that multiple clinical study results of mazdutide (GLP1R/GCGR dual agonist) will be presented at the European Association for the Study of Diabetes® (EASD) 60th An ...